

[illegible]

FIGURE 2

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA34392

<subunit 1 of 1, 379 aa, 1 stop

<MW: 43302, pI: 7.30, NX(S/T): 1

MKEYVLLLFLALCSAKPFFSPSHIALKNMMLKDMEDTDDDDDDDDDDDDDEDNSLFPTREPR
SHFFPFDLFPMCPFGCQCYSRVVHCSDLGLTSVPTNIPFDTRMLDLQNNKIKEIKENDFKGL
TSLYGLILNNNKLTKIHPKAFLTTKKLRRLYLSHNQLSEIPLNLPKSLAELRIHENKVKKIQ
KDTFKGMNALHVLEMSANPLDNNGIEPGAFEGVTVFHIRIAEAKLTSVPKGLPPTLLELHLD
YNKISTVELEDFKRYKELQRLGLGNNKITDIENGLANI PRVREIHLENNKLKKIPSGLP
KYLQIIIFLHSNSIARVGVNDFCPTVPKMKKSLYSAISLFNNPVKYWEMQPATFRCVLSRMSV
QLGNFGM

Signal sequence.

amino acids 1-15

N-glycosylation site.

amino acids 281-285

N-myristoylation sites.

amino acids 129-135, 210-216, 214-220, 237-243, 270-276, 282-288

Leucine zipper pattern.

amino acids 154-176

100EED"2E44h50

FIGURE 3

CGGACGCGTGCGGCGGACGCGTGCGGCCGCGSGCACCGCCCCGGCCCCGCGCCCTCCGCCCCCGCACTCGCGCCTCC
CTCCCTCCGCCCCGCTCCCGCGCCCTCCTCCCTCCCTCCCTCCCCAGCTGTCCCGTTTCGCGTCA**ATG**CCGAGCCTCCC
GGCCCCGCGCGCCCCGCTGCTGCTCCTCGGGCTGCTGCTGCTCGGCTCCCGCGCGGCCCGCGCGCCGCCCCAGA
GCCCCCGTGCTGCCATCCGTTCTGAGAAGGAGCCGCTGCCCGTTTCGGGGAGCGGCAGGCTGCACCTTCGGCGG
GAAGGTCTATGCCTTGACGAGACGTGGCACCCGGACCTAGGGCAGCCATTCGGGGTGATGCGCTGCGTGCTGTG
CGCCTGCGAGGCGCCTCAGTGGGGTCGCCGTACCAGGGGCCCTGGCAGGGTCAGCTGCAAGAACATCAAACCAGA
GTGCCCAACCCCGCCCTGTGGGCAGCCGCGCCAGCTGCCGGGACACTGCTGCCAGACCTGCCCCAGGAGCGCAG
CAGTTCGGAGCGGCAGCCGAGCGGCCTGTCTTCAGATATCCGCGGGACCCGGAGCATCGCAGTTATAGCGACCG
CGGGGAGCCAGGCGCTGAGGAGCGGGCCCGTGGTGACGGCCACACGGACTTCGTGGCGCTGCTGACAGGGCCGAG
GTGCGCAGGCGGTGGCACGAGCCCGAGTCTCGCTGCTGCGCTCTAGCCTCCGCTTCTCTATCTCCTACAGGCGGCT
GGACCGCCCTACCAGGATCCGCTTCTCAGACTCCAATGGCAGTGCTCTGTTTGAGCACCCCTGCAGCCCCACCCA
AGATGGCCTGGTCTGTGGGGTGTTGGCGGGCAGTGCCCTCGGTTGTCTCTGCGGCTCCTTAGGGCAGAACAGCTGCA
TGTGGCACTTGTGACACTCACTACCCCTCAGGGGAGGTCTGGGGGCCCTCTCATCCGGCACCGGGCCCTGGCTGC
AGAGACCTTCAGTGCCATCCTGACTCTAGAAGGCCCCCCACAGCAGGGCGTAGGGGGCATCACCTGCTCACTCT
CAGTGACACAGAGGACTCCTTGCAATTTTTTGCTGCTCTTCCGAGGGCTGCTGGAAACCCAGGAGTGGGGGACTAAC
CCAGGTTCCCTTGAGGCTCCAGATTCTACACCAGGGGCAGCTACTGCGAGAACTTCAGGCCAATGTCTCAGCCCA
GGAACAGGCTTTGCTGAGGTGCTGCCCAACCTGACAGTCCAGGAGATGGACTGGCTGGTGCTGGGGGAGCTGCA
TAGGCCCTGGAGTGGGCAGGCAGGCCAGGGCTGCGCATCAGTGACACATTGCTGCCAGGAAGAGCTGCGACGT
CCTGCAAAAGTGCTCTTTGTGGGGCTGATGCCCTGATCCAGTCCAGACGGGTGCTGCCGGCTCAGCCAGCCTCAC
GCTGCTAGGAAATGGCTCCCTGATCTATCAGGTGCAAGTGTTAGGGACAAGCAGTGAGGTGGTGGCCATGACACT
GGAGACCAAGCCTCAGCGGAGGGATCAGCGCACTGTCTGTGCCACATGGCTGGACTCCAGCCAGGAGGACACAC
GGCCGTGGGTATCTGCCCTGGGCTGGGTGCCCGAGGGGCTCATATGCTGCTGCAGAAAGAGCTCTTCTGAACGT
GGGCACCAAGGACTTCCAGACGGAGAGCTTCGGGGGCACGTGGCTGCCCTGCCCTACTGTGGGCATAGCGCCG
CCATGACACGCTGCCCGTGCCCTAGCAGGAGCCCTGGTGCTACCCCTGTGAAGAGCCAAGCAGCAGGGCACGC
CTGGCTTTCTTGGATACCCACTGTCACCTGCACTATGAAGTGCTGCTGGCTGGGCTTGGTGGCTCAGAACAAGG
CACTGTCACTGCCCACCTCCTTGGGCCCTCCTGGAACGCCAGGGCCTCGGCGGCTGCTGAAGGGATTCTATGGCTC
AGAGGCCCAGGGTGTGGTGAAGGACCTGGAGCCGGAAGTGTGCGGCACCTGGCAAAAGGCATGGCCTCCCTGAT
GATCACCAACCAAGGGTAGCCCCAGAGGGGAGCTCCGAGGGCAGGTGCACATAGCCAACCAATGTGAGGTTGGCGG
ACTGCGCCTGGAGGCGGCCGGGGCCGAGGGGTGCGGGCGCTGGGGGCTCCGGATACAGCCTCTGCTGCGCCGCC
TGTGGTGCTGGTCTCCCGGCCCTAGCGCCCGCCAAACCTGGTGGTCTGGGCGGCCCACTACGACCCGCTCTGCTCACTCTGCAC
CTGCCAGAGACGAACGGTGATCTGTGACCCGGTGGTGTGCCACCGCCAGCTGCCACACCCGGTGCAGGCTCC
CGACAGTGCTGCCCTGTTGCCCTGAGAAACAAGATGTGAGAGACTTGCCAGGGCTGCCAAGGAGCCGGGACCC
AGGAGAGGGCTGCTATTTTGATGGTGACCGGAGCTGGCGGGCAGCGGTACGCGGTGGCACCCCGTTGTGCCCCC
CTTTGGCTTAATTAAGTGCTGTCTGCACCTGCAAGGGGGGCACTGGAGAGGTGCACTGTGAGAAGGTGCAGTG
TCCCGGCTGGCCTGTGCCAGCCTGTGCGTGTCAACCCACCGACTGCTGCAAAACAGTGTCAGTGGGGTCCGG
GGCCACCCCAAGCTGGGGGACCCCATGCAGGCTGATGGGCCCCGGGGCTGCCGTTTTGCTGGGCAGTGTTCCC
AGAGAGTCAGAGCTGGCACCCCTCAGTGCCCCCTTTTGGAGAGATGAGCTGTATCACTGCAGATGTGGGGCAGG
GGTGCCTCACTGTGAGCGGGATGACTGTTCACTGCCACTGTCTGTGGCTCGGGGAAGGAGAGTCGATGCTGTTT
CCGCTGCACGGCCACCGGCGGCCCCAGAGACCAGAACTGATCCAGAGCTGGAGAAAGAAGCCGAAGGCTCT**TA**
GGGAGCAGCCAGAGGGCCAAGTGACCAAGAGGATGGGGCTGAGCTGGGGAAGGGGTGGCATCGAGGACCTTCTT
GCATTCTCCTGTGGGAAGCCAGTGCCCTTTGCTCCTCTGTCTGCTCTACTCCACCCCACTACCTCTGGGAA
CCACAGCTCCACAAGGGGGAGAGGCAGCTGGGCCAGACCGAGGTACAGCCACTCCAAGTCTGCCCTGCCACCC
TCGGCCTCTGTCTGGAAGCCCCACCCCTTTCTCCTGTACATAATGTCACTGGCTTGTGGGATTTTTAATTTA
TCTTCACTCAGCACCAAGGGCCCCGACACTCCACTCCTGCTGCCCTGAGCTGAGCAGAGTCATTATTGGAGAG
TTTTGTATTTATTAAACATTTCTTTTTTCAGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

CGGACGCGTGCGGCGGACGCGTGCGGCCGCGSGCACCGCCCCGGCCCCGCGCCCTCCGCCCCCGCACTCGCGCCTCC

FIGURE 5

GGCGGAGCAGCCCTAGCCGCCACCGTCGCTCTCGCAGCTCTCGTCGCCACTGCCACCGCCGCCGCGTCACTGCG
TCCTGGCTCCGGCTCCCGCGCCCTCCCGGCCGCCATGCAGCCCCGCCGCGCCAGGCGCCCGGTGCGCAGCTGC
TGCCCCGCGCTGGCCCTGCTGCTGCTGCTGCTCGGAGCGGGGCCCCGAGGCAGCTCCCTGGCCAACCCGGTGCCCG
CCGCGCCCTTGTCTGCGCCCGGGCCGTGCGCCGCGCAGCCCTGCCGGAATGGGGGTGTGTGCACCTCGCGCCCTG
AGCCGGACCCCGCAGCACCCGGCCCCCGCCGGCGAGCCTGGCTACAGCTGCACCTGCCCGCCCGGGATCTCCGGCG
CCAACTGCCAGCTTGTGTCAGATCCTTGTGCCAGCAACCCCTTGTCAACATGGCAACTGCAGCAGCAGCAGCAGCA
GCAGCAGCGATGGCTACCTCTGCATTTGCAATGAAGGCTATGAAGGTCCCAACTGTGAACAGGCACCTTCCAGTC
TCCAGCCACTGGCTGGACCGAATCCATGGCACCCCGACAGCTTCAGCCTGTTCTTGTCTACTCAGGAGCCTGACA
AAATCCTGCCTCGCTCTCAGGCAACGGTGACACTGCCTACCTGGCAGCCGAAAAACAGGGCAGAAAGTTGTAGAAA
TGAAATGGGATCAAGTGGAGGTGATCCAGATATTGCCTGTGGGAATGCCAGTTCTAACAGCTCTGCGGGTGGCC
GCCTGGTATCCTTTGAAGTGCCACAGAACACCTCAGTCAAGATTTCGGCAAGATGCCACTGCCTCACTGATTTTGC
TCTGGAAGGTCACGGCCACAGGATTCCAACAGTGTCTCCTCATAGATGGACGAAGTGTGACCCCCCTTCAGGCTT
CAGGGGGACTGGTCTCTCTGGAGGAGATGCTCGCCTGGGGAATAATCACTTTATTGGTTTTGTGAATGATTCTG
TGACTAAGTCTATTGTGGCTTTGCGCTTAACTCTGGTGGTGAAGGTCAGACCTGTGTGCCGGGGAGAGTCACG
CAAATGACTTGGAGTGTTCAGGAAAAGGAAAATGCACCACGAAGCCGTCAGAGGCAACTTTTTCCTGTACCTGTG
AGGAGCAGTACGTGGGTACTTTCTGTGAAGAATACGATGCTTGCCAGAGGAAAACCTTGCCAAAACAACGCGAGCT
GTATTGATGCAATGAAAAGCAAGATGGGAGCAATTTACCTGTGTTTGCCTTCTGTGTTATACTGGAGAGCTTT
GCCAGTCCAAGATTGATTACTGCATCCTAGACCCATGCAGAAATGGAGCAACATGCATTTCCAGTCTCAGTGGAT
TCACCTGCCAGTGTCCAGAAGGATACTTCGGATCTGCTTGTGAAGAAAAGGTGGACCCCTGCGCCTCGTCTCCGT
GCCAGAACAACGGCACCTGCTATGTGGACGGGGTACACTTTACCTGCAACTGCAGCCCGGGCTTACAGGGCCGA
CCTGTGCCCAGCTTATTGACTTCTGTGCCCTCAGCCCTGTGCTCATGGCACGTGCCGCGAGCGTGGGCACCAGCT
ACAAATGCCTCTGTGATCCAGGTTACCATGGCCTCTACTGTGAGGAGGAATATAATGAGTGCCTCTCCGCTCCAT
GCCTGAATGCAGCCACCTGCAGGGACCTCGTTAATGGCTATGAGTGTGTGTGCCTGGCAGAATACAAAGGAACAC
ACTGTGAATTGTACAAGGATCCCTGCGCTAACGTGAGTGTCTGAACGGAGCCACCTGTGACAGCGACGGCCTGA
ATGGCACGTGCATCTGTGCACCCGGGTTTACAGGTGAAGAGTGCACATTGACATAAATGAATGTGACAGTAACC
CCTGCCACCATGGTGGGAGCTGCCTGGACCAGCCCAATGGTTATAACTGCCACTGCCCGCATGGTTGGGTGGGAG
CAAATGTGAGATCCACCTCCAATGGAAGTCCGGGCACATGGCGGAGAGCCTCACCAACATGCCACGGCACTCCC
TCTACATCATCATTGGAGCCCTCTGCGTGGCCTTCATCCTTATGCTGATCATCTGATCGTGGGGATTGCGCGCA
TCAGCCGCATTGAATACCAGGGTTCTTCCAGGCCAGCCTATGAGGAGTTCTACAACTGCCGCGAGCATCGACAGCG
AGTTGAGCAATGCCATTGCATCCATCCGGCATGCCAGGTTTGGAAAGAAATCCCGGCCTGCAATGTATGATGTGA
GCCCCATCGCCTATGAAGATTACAGTCCTGATGACAAACCCCTGGTGCACACTGATTAATACTAAAGATTTGTAAT
CTTTTTTTGGATTATTTTTTCAAAAAGATGAGATACTACACTCATTTAAATATTTTTTAAGAAAATAAAAAGCTTAA
GAAATTTAAATGCTAGCTGCTCAAGAGTTTTTCAGTAGAATATTTAAGAACTAATTTTCTGCAGCTTTTAGTTTG
GAAAAATATTTTTAAAAACAAAATTTGTGAAACCTATAGACGATGTTTTAATGTACCTTCAGCTCTCTAACTGT
GTGCTTCTACTAGTGTGTGCTTTTTCACTGTAGACACTATCACGAGACCCAGATTAATTTCTGTGGTTGTTACA
GAATAAGTCTAATCAAGGAGAAGTTTCTGTTTGACGTTTGAGTGCCGGCTTTCTGAGTAGAGTTAGGAAAACCAC
GTAACGTAGCATATGATGTATAATAGAGTATACCCGTTACTTAAAAAGAAGTCTGAAATGTTCTGTTTGTGGAAA
AGAACTAGTTAAATTTACTATTCTTAACCCGAATGAAATTAGCCTTTGCCTTATTCTGTGCATGGGTAAGTAAC
TTATTTCTGCACTGTTTTGTTGAACTTTGTGGAAACATTCTTTCGAGTTTGTGTTTGTGTCATTTCTGTAACAGTCG
TCGAACTAGGCCTCAAAAACATACGTAACGAAAAGGCCTAGCGAGGCAAATTCTGATTGATTGAATCTATATTT
TTCTTTAAAAAGTCAAGGGTTCTATATTGTGAGTAAATTAAATTTACATTTGAGTTGTTTGTGCTAAGAGGTAG
TAAATGTAAGAGAGTACTGGTTCCCTTCAGTAGTGAGTATTTCTCATAGTGCAGCTTTATTTATCTCCAGGATGTT
TTTGTGGCTGTATTTGATTGATATGTGCTTCTTCTGATTCTTGCTAATTTCCAACCATATTGAATAAATGTGATC
AAGTCA

bioRxiv preprint doi: <https://doi.org/10.1101/2021.04.15.438444>; this version posted April 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

[illegible]

><MW: 78475, pI: 5.09, NX(S/T): 11

Signal sequence.

Transmembrane domain.

N-glycosylation sites.

Glycosaminoglycan attachment site.

Tyrosine kinase phosphorylation sites.

N-myristoylation sites.

Amidation site.

Aspartic acid and asparagine hydroxylation site.

EGF-like domain cysteine pattern signatures.

amino acids 80-92, 121-133, 336-348, 378-390, 416-428, 454-466,
491-503, 529-541, 567-579, 605-617

FIGURE 7

CTCTGGAAGGTCACGGCCACAGGATTCCAACAGTGCTCCCTCATAGATGGACGAAAGTGTGA
CCCCCCTTTCAGGCTTTCAGGGGGACTGGTCCTCCTGGAGGAGATGCTCGCCTTGGGGAATA
ATCACTTTATTGGTTTTGTGAATGATTCTGTGACTAAGTCTATTGTGGCTTTGCGCTTAACT
CTGGTGGTGAAGGTCAGCACCTGTGTGCCGGGGGAGAGTCACGCAAATGACTTGGAGTGTTT
AGGAAAAGGAAAATGCACCACGAAGCCGTCAGAGGCAACTTTTTCTGTACCTGTGAGGAGC
AGTACGTGGGTACTTTCTGTGAAGAATACGATGCTTGCCAGAGGAAACCTTGCCAAAACAAC
GCGAGCTGTATTGATGCAAATGAAAAGCAAGATGGGAGCAATTTACCTGTGTTTGCCTTCC
TGGTTATACTGGAGAGCTTTGCCAACCGAACTGAGATTGGAGCGAACGACCTACACCGAACT
GAGATAGGGGAG

094432.083001
"2E44650"

FIGURE 8

CTCTGGAAGGTCACGGCCACAGGATTCCAACAGTGCTCCCTCATAGATGGACGAAAGTGTGA
CCCCCCTTTCAGGCTTTCAGGGGGACTGGTCCTCCTGGAGGAGATGCTCGCCTTGGGGAATA
ATCACTTTATTGGTTTTGTGAATGATTCTGTGACTAAGTCTATTGTGGCTTTGCGCTTAAC
CTGGTGGTGAAGGTCAGCACCTGTGTGCCGGGGGAGAGTCACGCAAATGACTTGGAGTGTT
AGGAAAAGGAAAATGCACCACGAAGCCGTCAGAGGCAACTTTTTCTGTACCTGTGAGGAGC
AGTACGTGGGTACTTTCTGTGAAGAATACGATGCTTGCCAGAGGAAACCTTGCCAAAACAAC
GCGAGCTGTATTGATGCAAATGAAAAGCAAGATGGGAGCAATTTACCTGTGTTTGCCTTCC
TGGTTATACTGGAGAGCTTTGCCAACCGAACTGAGATTGGAGCGAACGACCTACACCGAACT
GAGATAGGGGAG

09443-03001
"2444650"

[illegible]

GCTGAGTCTGCTGCTCCTGCTGCTGCTGCTCCAGCCTGTAACCTGTGCCTACACCACGCCAG
GCCCCCCCAGAGCCCTCACCACGCTGGGCGCCCCCAGAGCCCACACCATGCCGGGCACCTAC
GCTCCCTCGACCACACTCAGTAGTCCCAGCACCCAGGGCCTGCAAGAGCAGGCACGGGGCCCT
GATGCGGGACTTCCCGCTCGTGGACGGCCACAACGACCTGCCCCTGGTCCTAAGGCAGGTTT
ACCAGAAAGGGCTACAGGATGTTAACCTGCGCAATTTTCAGCTACGGCCAGACCAGCCTGGAC
AGGCTTAGAGATGGCCTCGTGGGCGCCCAGTTCTGGTCAGCCTATGTGCCATGCCAGACCCA
GGACCGGGATGCCCTGCGCCTCACCTGGAGCAGATTGACCTCATACGCCGCATGTGTGCCT
CCTATTCTGAGCTGGAGCTTGTGACCTCGGCTAAAGCTCTGAACGACACTCAGAAATTGGCC
TGCCTCATCGGTGTAGAGGGTGGCCACTCGCTGGACAATAGCCTCTCCATCTTACGTACCTT
CTACATGCTGGGAGTGCCTACCTGACGCTCACCCACACCTGCAACACACCCTGGGCAGAGA
GCTCCGCTAAGGGCGTCCACTCCTTCTACAACAACATCAGCGGGCTGACTGACTTTGGTGAG
AAGGTGGTGGCAGAAATGAACCGCCTGGGCATGATGGTAGACTTATCCCATGTCTCAGATGC
TGTGGCACGGCGGGCCCTGGAAGTGTACAGGCACCTGTGATCTTCTCCCACTCGGCTGCCC
GGGGTGTGTGCAACAGTGCTCGGAATGTTCCCTGATGACATCCTGCAGCTTCTGAAGAAGAAC
GGTGGCGTCGTGATGGTGTCTTTGTCCATGGGAGTAATACAGTGCAACCCATCAGCCAATGT
GTCCACTGTGGCAGATCACTTCGACCACATCAAGGCTGTCATTGGATCCAAGTTCATCGGGA
TTGGTGGAGATTATGATGGGGCCGGCAAATTCCTCAGGGGCTGGAAGACGTGTCCACATAC
CCGGTCCTGATAGAGGAGTTGCTGAGTCGTGGCTGGAGTGAGGAAGAGCTTCAGGGTGTCTCT
TCGTGGAAACCTGCTGCGGGTCTTCAGACAAGTGGAAAAGGTACAGGAAGAAAACAAATGGC
AAAGCCCCTTGGAGGACAAGTTCCCGGATGAGCAGCTGAGCAGTTCTTGCCACTCCGACCTC
TCACGTCTGCGTCAGAGACAGAGTCTGACTTCAGGCCAGGAACTCACTGAGATTCCCATACA
CTGGACAGCCAAGTTACCAGCCAAGTGGTCAGTCTCAGAGTCCTCCCCCACATGGCCCCAG
TCCTTGCAAGTTGTGGCCACCTTCCCAGTCCTTATTCTGTGGCTCTGATGACCCAGTTAGTCC
TGCCAGATGTCACTGTAGCAAGCCACAGACACCCACAAAGTTCCCCTGTTGTGCAGGCACA
AATATTTCTGAAATAAATGTTTTGGACATAG

TABLE 1	
Summary of the study	
Variable	Value
Study design	Retrospective cohort study
Study period	1990-1999
Study location	United States
Study population	1,000,000
Study outcome	Incidence of disease
Study results	1.0
Study limitations	1.0
Study strengths	1.0
Study conclusions	1.0
Study implications	1.0
Study significance	1.0
Study relevance	1.0
Study validity	1.0
Study reliability	1.0
Study generalizability	1.0
Study applicability	1.0
Study transferability	1.0
Study adaptability	1.0
Study flexibility	1.0
Study robustness	1.0
Study resilience	1.0
Study durability	1.0
Study sustainability	1.0
Study feasibility	1.0
Study acceptability	1.0
Study desirability	1.0
Study ethicality	1.0
Study legality	1.0
Study morality	1.0
Study justice	1.0
Study equity	1.0
Study fairness	1.0
Study honesty	1.0
Study integrity	1.0
Study transparency	1.0
Study accountability	1.0
Study responsibility	1.0
Study stewardship	1.0
Study governance	1.0
Study leadership	1.0
Study management	1.0
Study organization	1.0
Study structure	1.0
Study culture	1.0
Study values	1.0
Study beliefs	1.0
Study attitudes	1.0
Study behaviors	1.0
Study practices	1.0
Study policies	1.0
Study procedures	1.0
Study protocols	1.0
Study standards	1.0
Study guidelines	1.0
Study recommendations	1.0
Study conclusions	1.0
Study implications	1.0
Study significance	1.0
Study relevance	1.0
Study validity	1.0
Study reliability	1.0
Study generalizability	1.0
Study applicability	1.0
Study transferability	1.0
Study adaptability	1.0
Study flexibility	1.0
Study robustness	1.0
Study resilience	1.0
Study durability	1.0
Study sustainability	1.0
Study feasibility	1.0
Study acceptability	1.0
Study desirability	1.0
Study ethicality	1.0
Study legality	1.0
Study morality	1.0
Study justice	1.0
Study equity	1.0
Study fairness	1.0
Study honesty	1.0
Study integrity	1.0
Study transparency	1.0
Study accountability	1.0
Study responsibility	1.0
Study stewardship	1.0
Study governance	1.0
Study leadership	1.0
Study management	1.0
Study organization	1.0
Study structure	1.0
Study culture	1.0
Study values	1.0
Study beliefs	1.0
Study attitudes	1.0
Study behaviors	1.0
Study practices	1.0
Study policies	1.0
Study procedures	1.0
Study protocols	1.0
Study standards	1.0
Study guidelines	1.0
Study recommendations	1.0
Study conclusions	1.0
Study implications	1.0
Study significance	1.0
Study relevance	1.0
Study validity	1.0
Study reliability	1.0
Study generalizability	1.0
Study applicability	1.0
Study transferability	1.0
Study adaptability	1.0
Study flexibility	1.0
Study robustness	1.0
Study resilience	1.0
Study durability	1.0
Study sustainability	1.0
Study feasibility	1.0
Study acceptability	1.0
Study desirability	1.0
Study ethicality	1.0
Study legality	1.0
Study morality	1.0
Study justice	1.0
Study equity	1.0
Study fairness	1.0
Study honesty	1.0
Study integrity	1.0
Study transparency	1.0
Study accountability	1.0
Study responsibility	1.0
Study stewardship	1.0
Study governance	1.0
Study leadership	1.0
Study management	1.0
Study organization	1.0
Study structure	1.0
Study culture	1.0
Study values	1.0
Study beliefs	1.0
Study attitudes	1.0
Study behaviors	1.0
Study practices	1.0
Study policies	1.0
Study procedures	1.0
Study protocols	1.0
Study standards	1.0
Study guidelines	1.0
Study recommendations	1.0
Study conclusions	1.0
Study implications	1.0
Study significance	1.0
Study relevance	1.0
Study validity	1.0
Study reliability	1.0
Study generalizability	1.0
Study applicability	1.0
Study transferability	1.0
Study adaptability	1.0
Study flexibility	1.0
Study robustness	1.0
Study resilience	1.0
Study durability	1.0
Study sustainability	1.0
Study feasibility	1.0
Study accept	

MPGTYAPSTTLSSPSTQGLQEQARALMRDFPLVDGHNDLPLVLRQVYQKGLQDVNLRNFSYG
QTSLDRLRDGLVGAQFWSAYVPCQTQDRDALRLTLEQIDLIIRMCASYSELELVTSAKALND
TQKLACLIGVEGGHSLDNSLSILRTFYMLGVRYLTLTHTCNTPWAESSAKGVHSFYNNISGL
TDFGEKVVAEMNRLGMMVDLSHVSDAVARRALEVSQAPVIFSHSAARGVCNSARNVPDDILQ
LLKKNGGVVMVSLSMGVIQCNP SANVSTVADHFDHIKAVIGSKFIGIGGDYDGAGKFPQGLE
DVSTYPVLI EELLSRGWSEELQGVLRGNLLRVFRQVEKVQEENKWQSPLEDKFPDEQLSSS
CHSDLSRLROROSLTSGOELTEIPIHWTAKLPAKWSVSESSPHMAPVLAVVATFPVLILWL

amino acids 58-62, 123-127, 182-186, 273-277

amino acids 72-78, 133-139, 234-240, 264-270, 334-340, 389-395

amino acids 134-157

[illegible]

AAAACCTATAAATATTCCGGATTATTTCATACCGTCCCACCATCGGGCGGGATCCGCGGCCG
CGAATTCTAAACCAACATGCCGGGCACCTACGCTCCCTCGACCACACTCAGTAGTCCCAGCA
CCCAGGGCCTGCAAGAGCAGGCACGGGGCCCTGATGCGGGACTTCCCGCTCGTGGACGGCCAC
AACGACCTGCCCCCTGGTCCTAAGGCAGGTTTACCAGAAAGGGCTACAGGATGTTAACCTGCG
CAATTTTCAGCTACGGCCAGACCAGCCTGGACAGGCTTAGAGATGGCCTCGTGGGCGCCCAGT
TCTGGTCAGCCTATGTGCCATGCCAGACCCAGGACCGGGATGCCCTGCGCCTCACCTGGAG
CAGATTGACCTCATACGCCGCATGTGTGCCTCCTATTCTGAGCTGGAGCTTGTGACCTCGGC
TAAAGCTCTGAACGACACTCAGAAATTGGCCTGCCTCATCGGTGTAGAGGGTGGCCACTCGC
TGGACAATAGCCTCTCCATCTTACGTACCTTCTACATGCTGGGAGTGCCTACCTGACGCTC
ACCCACACCTGCAACACACCCTGGGCAGAGAGCTCCGCTAAGGGCGTCCACTCCTTCTACAA
CAACATCAGCGGGCTGACTGACTTTGGTGAGAAGGTGGTGGCAGAAATGAACCGCCTGGGCA
TGATGGTAGACTTATCCCATGTCTCAGATGCTGTGGCACGGCGGGGCCCTGGAAGTGTACAG
GCACCTGTGATCTTCTCCCACTCGGCTGCCCCGGGGTGTGTGCAACAGTGCTCGGAATGTTCC
TGATGACATCCTGCAGCTTCTGAAGAAGAACGGTGGCGTTCGTGATGGTGTCTTTGTCCATGG
GAGTAATACAGTGCAACCCATCAGCCAATGTGTCCACTGTGGCAGATCACTTCGACCACATC
AAGGCTGTCAATTGGATCCAAGTTCATCGGGATTGGTGGAGATTATGATGGGGCCGGCAAATT
CCCTCAGGGGCTGGAAGACGTGTCCACATAACCGGTCCTGATAGAGGAGTTGCTGAGTCGTG
GCTGGAGTGAGGAAGAGCTTCAGGGTGTCTTCGTGGAAACCTGCTGCGGGTCTTCAGACAA
GTGGAAAAGGTACAGGAAGAAAACAAATGGCAAAGCCCCTTGGAGGACAAGTTCCCGGATGA
GCAGCTGAGCAGTTCTTGCCTACTCCGACCTCTCACGTCTGCGTCAGAGACAGAGTCTGACTT
CAGGCCAGGAACTCACTGAGATTCCCATACACTGGACAGCCAAGTTACCAGCCAAGTGGTCA
GTCTCAGAGTCCTCCCCCACCCTGACAAAACCTCACACATGCCACCGTGCCCAGCACCTGA
ACTCCTGGGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCCAAGGACACC

General Information	
Study ID	1001
Version	1.0
Date	2023-10-27
Author	John Doe
Reviewer	Jane Smith
Approval Date	2023-11-01
Study Objectives	
Primary Objective	To evaluate the efficacy of the new drug compared to the placebo.
Secondary Objectives	To assess the safety and tolerability of the new drug.
Study Design	Randomized, double-blind, placebo-controlled trial.
Study Population	Adults aged 18-65 years with mild to moderate disease.
Study Sites	10 sites across 5 countries.
Study Duration	12 weeks.
Study Arms	New Drug (N=100) and Placebo (N=100).
Study Endpoints	Primary: Change in disease severity score. Secondary: Adverse events.
Study Results	Primary endpoint met. New Drug group showed significantly greater improvement in disease severity score compared to placebo (p < 0.05).
Study Conclusions	The new drug is effective and safe for the treatment of the disease.
Study Limitations	Short duration, limited to mild to moderate disease.
Study Recommendations	Further studies are needed to confirm the findings and evaluate the drug in more severe cases.
Study References	1. Smith J, Doe J. (2023) Efficacy of New Drug in Treating Disease. <i>Journal of Medicine</i> . 2. Doe J, Smith J. (2023) Safety and Tolerability of New Drug. <i>Journal of Medicine</i> .
Study Appendix	See Appendix A for full study protocol and statistical analysis.

General Information	
Study ID	1001
Version	1.0
Date	2023-10-27
Author	John Doe
Reviewer	Jane Smith
Approval Date	2023-11-01
Study Objectives	
Primary Objective	To evaluate the efficacy of the new drug compared to the placebo.
Secondary Objectives	To assess the safety and tolerability of the new drug.
Study Design	Randomized, double-blind, placebo-controlled trial.
Study Population	Adults aged 18-65 years with mild to moderate disease.
Study Sites	10 sites across 5 countries.
Study Duration	12 weeks.
Study Arms	New Drug (N=100) and Placebo (N=100).
Study Endpoints	Primary: Change in disease severity score. Secondary: Adverse events.
Study Results	Primary endpoint met. New Drug group showed significantly greater improvement in disease severity score compared to placebo (p < 0.05).
Study Conclusions	The new drug is effective and safe for the treatment of the disease.
Study Limitations	Short duration, limited to mild to moderate disease.
Study Recommendations	Further studies are needed to confirm the findings and evaluate the drug in more severe cases.
Study References	1. Smith J, Doe J. (2023) Efficacy of New Drug in Treating Disease. <i>Journal of Medicine</i> . 2. Doe J, Smith J. (2023) Safety and Tolerability of New Drug. <i>Journal of Medicine</i> .
Study Appendix	See Appendix A for full study protocol and statistical analysis.

General Information	
Study ID	1001
Version	1.0
Date	2023-10-27
Author	John Doe
Reviewer	Jane Smith
Approval Date	2023-11-01
Study Objectives	
Primary Objective	To evaluate the efficacy of the new drug compared to the placebo.
Secondary Objectives	To assess the safety and tolerability of the new drug.
Study Design	Randomized, double-blind, placebo-controlled trial.
Study Population	Adults aged 18-65 years with mild to moderate disease.
Study Sites	10 sites across 5 countries.
Study Duration	12 weeks.
Study Arms	New Drug (N=100) and Placebo (N=100).
Study Endpoints	Primary: Change in disease severity score. Secondary: Adverse events.
Study Results	Primary endpoint met. New Drug group showed significantly greater improvement in disease severity score compared to placebo (p < 0.05).
Study Conclusions	The new drug is effective and safe for the treatment of the disease.
Study Limitations	Short duration, limited to mild to moderate disease.
Study Recommendations	Further studies are needed to confirm the findings and evaluate the drug in more severe cases.
Study References	1. Smith J, Doe J. (2023) Efficacy of New Drug in Treating Disease. <i>Journal of Medicine</i> . 2. Doe J, Smith J. (2023) Safety and Tolerability of New Drug. <i>Journal of Medicine</i> .
Study Appendix	See Appendix A for full study protocol and data.

General Information	
Study ID	1001
Version	1.0
Date	2023-10-27
Author	John Doe
Reviewer	Jane Smith
Approval Date	2023-11-01
Study Objectives	
Primary Objective	To evaluate the efficacy of the new drug compared to the placebo.
Secondary Objectives	To assess the safety and tolerability of the new drug.
Study Design	Randomized, double-blind, placebo-controlled trial.
Study Population	Adults aged 18-65 years with mild to moderate disease.
Study Sites	10 sites across 5 countries.
Study Duration	12 weeks.
Study Arms	New Drug (N=100) and Placebo (N=100).
Study Endpoints	Primary: Change in disease severity score. Secondary: Adverse events.
Study Results	Primary endpoint met. New Drug group showed significantly greater improvement in disease severity score compared to placebo (p < 0.05).
Study Conclusions	The new drug is effective and safe for the treatment of the disease.
Study Limitations	Short duration, limited to mild to moderate disease.
Study Recommendations	Further studies are needed to confirm the findings and evaluate the drug in more severe cases.
Study References	1. Smith J, Doe J. (2023) Efficacy of New Drug in Treating Disease. <i>Journal of Medicine</i> . 2. Doe J, Smith J. (2023) Safety and Tolerability of New Drug. <i>Journal of Medicine</i> .
Study Appendix	See Appendix A for full study protocol and statistical analysis.

[illegible]

FIGURE 14

><ss.DNA38113

><subunit 1 of 1, 422 aa, 1 stop

><MW: 46302, pI: 9.42, NX(S/T): 6

MPAGRRGPAAQSARRPPPLLPLLLLLCVLGAPRAGSGAHTAVIS PQDPTLLIGSSLLATCSV
HGDPPGATAEGLYWTLNGRRLPPELSRVLNASTLALALANLNGSRQ RSGDNLVCHARDGSIL
AGSCLYVGLPPEKPVNISCWSKNMKDLTCRWTPGAHGETFLHTNYS LKYKLRWYGQDNTCEE
YHTVGPHSCHIPKDLALFTPYEIWVEATNRLGSARSVDVLTLDILDV VTTDPPPVDVHVS RVGG
LEDQLSVRWVSPPALKDFLFQAKYQIRYRVEDSV DWKVVDVSNQTSCRLAGLKPGTVYFVQ
VRCNPFGIYGSKKAGIWSEWSHPTAASTPRSERPGPGGGACEPRG GEPSSGPVRRELKQFLG
WLKKHAYCSNLSFRLYDQWRAWMQKSHKTRNQDEGILPSGRRGTARGPAR

Signal sequence.

amino acids 1-30

Transmembrane domain.

amino acids 44-61

N-glycosylation sites.

amino acids 92-96, 104-108, 140-144, 168-172, 292-296, 382-386

cAMP- and cGMP-dependent protein kinase phosphorylation site.

amino acids 413-417

N-myristoylation sites.

amino acids 30-36, 37-43, 73-79, 121-127, 179-185, 218-224,
300-306, 317-323, 320-326, 347-353, 355-361, 407-413

Amidation site.

amino acids 3-7, 79-83, 411-415

Growth factor and cytokines receptors family signature 2.

amino acids 325-331

100280" 2E444660

Socioeconomic Characteristics		Health Status		Healthcare Access		Healthcare Utilization		Healthcare Costs		Healthcare Outcomes			
Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)		
Age	45.2 (12.5)	Gender	Male (52.3%)	Marital Status	Married (68.5%)	Health Insurance	Private (75.2%)	Physician Visits	3.2 (2.1)	Prescription Drugs	4.5 (3.2)	Health Status	Good (78.5%)
Education	12.8 (2.1)	Income	\$35,200 (15,800)	Employment	Employed (65.2%)	Access to Care	High (82.1%)	Hospitalizations	1.8 (1.2)	Emergency Visits	0.5 (0.8)	Quality of Life	72.5 (15.2)
Health Status	Good (78.5%)	Healthcare Access	High (82.1%)	Healthcare Utilization	Physician Visits (3.2)	Healthcare Costs	\$1,250 (850)	Healthcare Outcomes	Health Status (78.5%)	Quality of Life	72.5 (15.2)		

[illegible]

FIGURE 16

</usr/seqdb2/sst/DNA/Dnaseqs.full/ss.DNA34436

<subunit 1 of 1, 300 aa, 1 stop

<MW: 32964, pI: 9.52, NX(S/T): 1

MKFLLDILLLLPLLIIVCSLESFVKLFIPKRRKSVTGEIVLITGAGHGIGRLTAYEFAKLKSK
LVLWDINKHGLEETAACKCKGLGAKVHTFVVDCSNREDIYSSAKKVKAIEIGDVSILVNNAGVV
YTSDLFATQDPQIEKTFEVNVLAHFWTTKAFLPAMTKNNHGHIVTVASAAGHVSVPFLLAYC
SSKFAAVGFHKTLTDELAALQITGVKTTCLCPNFVNTGFIKNPSTSLGPTLEPEEVNRLMH
GILTEQKMIFIPSSIAFLTTLERILPERFLAVLKRKISVKFDAVIGYKMKAQ

Signal sequence.

amino acids 1-19

Transmembrane domain.

amino acids 170-187

cAMP- and cGMP-dependent protein kinase phosphorylation sites.

amino acids 30-34, 283-287

N-myristoylation sites.

amino acids 43-49, 72-78, 122-128, 210-216

FIGURE 16

General Information		Identification		Physical Properties		Chemical Properties		Spectral Data		Elemental Analysis	
Name	Formula	Weight	Color	Melting Point	Boiling Point	Refractive Index	Density	IR (cm ⁻¹)	NMR (ppm)	Calcd	Found
1,2-Dichloroethane	C ₂ H ₄ Cl ₂	98.96	Colorless	-35.0	83.5	1.2756	1.2501	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,2,2-Tetrachloroethane	C ₂ H ₂ Cl ₄	167.03	Colorless	127.0	146.0	1.4720	1.4950	1260, 1030, 720	3.4, 2.6	62.03	62.05
1,1,1,2-Tetrachloroethane	C ₂ HCl ₃	181.39	Colorless	114.0	146						

[illegible]

```
><subunit 1 of 1, 243 aa, 1 stop
```

MRPLLVLALLGLAAGSPPLDDNKIPSLCPGHFGLPGTPGHHGSQGLPGRDGRDGRDGAPGAP
GEKGEGGRPGLPGPRGDPGPRGEAGPAGPTGPAGECSVPPRSAFSKRSESRVPPPSDAPLP
FDRVLVNEQGHYDAVTGKFTCQVPGVYYFAVHATVYRASLQFDLVKNGESIASFFQFFGGWP
KPASLSGGAMVRLEPEDQVWVQVGVDYIGIYASIKTDSTFSGFLVYSDWHSSPVFA

amino acids 1-15

amino acids 11-17, 68-74, 216-222

amino acids 77-80

Variable	Mean	SD	Min	Max
Age	38.5	12.5	18	65
Gender	0.5	0.5	0	1
Marital Status	0.7	0.5	0	1
Education	12.5	2.5	9	16
Income	3500	1500	1000	8000
Health	0.8	0.3	0	1
Stress	4.5	1.5	1	7
Depression	0.2	0.4	0	1
Loneliness	3.0	1.0	1	5
Life Satisfaction	5.5	1.5	1	9
Resilience	0.6	0.3	0	1
Optimism	0.7	0.3	0	1
Gratitude	0.8	0.3	0	1
Forgiveness	0.6	0.3	0	1
Compassion	0.7	0.3	0	1
Kindness	0.8	0.3	0	1
Generosity	0.7	0.3	0	1
Patience	0.6	0.3	0	1
Humility	0.7	0.3	0	1
Modesty	0.8	0.3	0	1
Self-control	0.7	0.3	0	1
Discipline	0.6	0.3	0	1
Perseverance	0.7	0.3	0	1
Determination	0.8	0.3	0	1
Confidence	0.7	0.3	0	1
Self-esteem	0.6	0.3	0	1
Self-worth	0.7	0.3	0	1
Self-respect	0.8	0.3	0	1
Self-love	0.7	0.3	0	1
Self-compassion	0.6	0.3	0	1
Self-forgiveness	0.7	0.3	0	1
Self-kindness	0.8	0.3	0	1
Self-generosity	0.7	0.3	0	1
Self-patience	0.6	0.3	0	1
Self-humility	0.7	0.3	0	1
Self-modesty	0.8	0.3	0	1
Self-discipline	0.7	0.3	0	1
Self-perseverance	0.6	0.3	0	1
Self-determination	0.7	0.3	0	1
Self-confidence	0.8	0.3	0	1
Self-esteem	0.7	0.3	0	1
Self-worth	0.6	0.3	0	1
Self-respect	0.7	0.3	0	1
Self-love	0.8	0.3	0	1
Self-compassion	0.7	0.3	0	1
Self-forgiveness	0.6	0.3	0	1
Self-kindness	0.7	0.3	0	1
Self-generosity	0.8	0.3	0	1
Self-patience	0.7	0.3	0	1
Self-humility	0.6	0.3	0	1
Self-modesty	0.7	0.3	0	1
Self-discipline	0.8	0.3	0	1
Self-perseverance	0.7	0.3	0	1
Self-determination	0.6	0.3	0	1
Self-confidence	0.7	0.3	0	1
Self-esteem	0.8	0.3	0	1
Self-worth	0.7	0.3	0	1
Self-respect	0.6	0.3	0	1
Self-love	0.7	0.3	0	1
Self-compassion	0.8	0.3	0	1
Self-forgiveness	0.7	0.3	0	1
Self-kindness	0.6	0.3	0	1
Self-generosity	0.7	0.3	0	1
Self-patience	0.8	0.3	0	1
Self-humility	0.7	0.3	0	1
Self-modesty	0.6	0.3	0	1
Self-discipline	0.7	0.3	0	1
Self-perseverance	0.8	0.3	0	1
Self-determination	0.7	0.3	0	1
Self-confidence	0.6	0.3	0	1
Self-esteem	0.7	0.3	0	1
Self-worth	0.8	0.3	0	1
Self-respect	0.7	0.3	0	1
Self-love	0.6	0.3	0	1
Self-compassion	0.7	0.3	0	1
Self-forgiveness	0.8	0.3	0	1
Self-kindness	0.7	0.3	0	1
Self-generosity	0.6	0.3	0	1
Self-patience	0.7	0.3	0	1
Self-humility	0.8	0.3	0	1
Self-modesty	0.7	0.3	0	1
Self-discipline	0.6	0.3	0	1
Self-perseverance	0.7	0.3	0	1
Self-determination	0.8	0.3	0	1

CTCTTTTGTGCCACCAGCCAGCCTGACTCCTGGAGATTGTGAATAGCTCCATCCAGCCTGAG
AAACAAGCCGGGTGGCTGAGCCAGGCTGTGCACGGAGCACCTGACGGGCCCAACAGACCCAT
GCTGCATCCAGAGACCTCCCCTGGCCGGGGGCATCTCCTGGCTGTGCTCCTGGCCCTCCTTG
GCACCACCTGGGCAGAGGTGTGGCCACCCAGCTGCAGGAGCAGGCTCCGATGGCCGGAGCC
CTGAACAGGAAGGAGAGTTTCTTGCTCCTCTCCCTGCACAACCGCCTGCGCAGCTGGGTCCA
GCCCCCTGCGGCTGACATGCGGAGGCTGGACTGGAGTGACAGCCTGGCCCAACTGGCTCAAG
CCAGGGCAGCCCTCTGTGGAATCCCAACCCCGAGCCTGGCATCCGGCCTGTGGCGCACCTG
CAAGTGGGCTGGAACATGCAGCTGCTGCCCCGCGGGCTTGGCGTCCTTTGTTGAAGTGGTCAG
CCTATGGTTTGCAGAGGGGCAGCGGTACAGCCACGCGGCAGGAGAGTGTGCTCGCAACGCCA
CCTGCACCCACTACACGCAGCTCGTGTGGGCCACCTCAAGCCAGCTGGGCTGTGGGCGGCAC
CTGTGCTCTGCAGGCCAGACAGCGATAGAAGCCTTTGTCTGTGCCTACTCCCCGGAGGCAA
CTGGGAGGTCAACGGGAAGACAATCATCCCTATAAGAAGGGTGCCTGGTGTTCGCTCTGCA
CAGCCAGTGTCTCAGGCTGCTTCAAAGCCTGGGACCATGCAGGGGGGCTCTGTGAGGTCCCC
AGGAATCCTTGTGCGATGAGCTGCCAGAACCATGGACGTCTCAACATCAGCACCTGCCACTG
CCACTGTCCCCCTGGCTACACGGGCAGATACTGCCAAGTGAGGTGCAGCCTGCAGTGTGTGC
ACGGCCGGTTCCGGGAGGAGGAGTGCTCGTGCGTCTGTGACATCGGCTACGGGGGAGCCAG
TGTGCCACCAAGGTGCATTTTCCCTTCCACACCTGTGACCTGAGGATCGACGGAGACTGCTT
CATGGTGTCTTCAGAGGCAGACACCTATTACAGAGCCAGGATGAAATGTCAGAGGAAAGGCG
GGGTGCTGGCCCAGATCAAGAGCCAGAAAGTGCAAGGACATCCTCGCCTTCTATCTGGGCCGC
CTGGAGACCACCAACGAGGTGACTGACAGTGACTTCGAGACCAGGAACTTCTGGATCGGGCT
CACCTACAAGACCGCCAAGGACTCCTTCCGCTGGGCCACAGGGGAGCACCAGGCCTTCACTA
GTTTTGCCTTTGGGCAGCCTGACAACCACGGGCTGGTGTGGCTGAGTGCTGCCATGGGGTTT
GGCAACTGCGTGGAGCTGCAGGCTTCAGCTGCCTTCAACTGGAACGACCAGCGCTGCAAAAC
CCGAAACCGTTACATCTGCCAGTTTGCCAGGAGCACATCTCCCGGTGGGGGCCAGGGTCCT
GAGGCCTGACCACATGGCTCCCTCGCCTGCCCTGGGAGCACCGGCTCTGCTTACCTGTCTGC
CCACCTGTCTGGAACAAGGGCCAGGTTAAGACCACATGCCTCATGTCCAAAGAGGTCTCAGA
CCTTGCACAATGCCAGAAGTTGGGCAGAGAGAGGCAGGGAGGCCAGTGAGGGCCAGGGAGTG
AGTGTTAGAAGAAGCTGGGGCCCTTCGCCTGCTTTTGATTGGGAAGATGGGCTTCAATTAGA
TGGCGAAGGAGAGGACACCGCCAGTGGTCCAAAAGGCTGCTCTCTTCCACCTGGCCCAGAC
CCTGTGGGGCAGCGGAGCTTCCCTGTGGCATGAACCCACGGGGTATTAAATTATGAATCAG
CTGAAAAAAAAAAAAA

[illegible]

<subunit 1 of 1, 455 aa, 1 stop

MLHPETSPGRGHLLAVLLALLGTTWAEVWPPQLQEQA PMAGALNRKESFLLLSLHNRLRSWV
QPPAADMRRLDWSDSL AQLAQARAALCGI PTPSLASGLWRTLQVGWNMQLLPAGLASFVEVV
SLWFAEGQRYSHAAGECARNATCTHYTQLVWATSSQLGCGRHLCSAGQTAIEAFVCAYSPGG
NWEVNGKTIIPYKKGAWCSLCTASVSGCFKAWDHAGGLCEVPRNPCRMSCQNHGRLNISTCH
CHCPPGYTGRYCQVRCSLQCVHGRFREEECSCVCDIGYGGAQCATKVHFFPHTCDLRIDGDC
FMVSSEADTYRARMKCQRKGGVLAQIKSQKVQDILAFYLGRL ETTNEVTDSDFETRNFwig
LTYKTAKDSFRWATGEHQAF TSFAFGQPDNHGLVWLSAAMGFGNCVELQASAAFNWNDQRCK
TRNRYICQFAQEHISRWGPGS

amino acids 1-26

amino acids 110-124

amino acids 144-148, 243-247

amino acids 45-49

amino acids 22-28, 99-105, 131-137, 201-207, 213-219, 287-293,
288-294, 331-337, 398-404

amino acids 204-215

amino acids 249-261, 280-292

amino acids 417-442

FIGURE 21

CGGACGCGTGGGCTGGGCGCTGCAAAGCGTGTCCCGCCGGGTCCCCGAGCGTCCCGCGCCCT
CGCCCCGCC**ATG**CTCCTGCTGCTGGGGCTGTGCCTGGGGCTGTCCCTGTGTGTGGGGTCGCA
GGAAGAGGCGCAGAGCTGGGGCCACTCTTCGGAGCAGGATGGACTCAGGGTCCCGAGGCAAG
TCAGACTGTTGCAGAGGCTGAAAACCAAACCTTTGATGACAGAATTCTCAGTGAAGTCTACC
ATCATTTCCCGTTATGCCTTCACTACGGTTTCTCCTGCAGAATGCTGAACAGAGCTTCTGAAGA
CCAGGACATTGAGTTCAGATGCAGATTCCAGCTGCAGCTTTCATCACCAACTTCACTATGC
TTATTGGAGACAAGGTGTATCAGGGCGAAATTACAGAGAGAGAAAAGAAGAGTGGTGATAGG
GTAAAAGAGAAAAGGAATAAAACACAGAAAGAAAATGGAGAGAAGGGGACTGAAATATTAG
AGCTTCTGCAGTGATTCCCAGCAAGGACAAAGCCGCTTTTTCTGAGTTATGAGGAGCTTC
TGCAGAGGCGCCTGGGCAAGTACGAGCACAGCATCAGCGTGCGGCCCCAGCAGCTGTCCGGG
AGGCTGAGCGTGGACGTGAATATCCTGGAGAGCGCGGGCATCGCATCCCTGGAGGTGCTGCC
GCTTCACAACAGCAGGCAGAGGGGCAGTGGGCGCGGGGAAGATGATTCTGGGCCTCCCCAT
CTACTGTCAATTAACCAAAATGAAACATTTGCCAACATAATTTTTTAAACCTACTGTAGTACAA
CAAGCCAGGATTGCCCAGAATGGAATTTTGGGAGACTTTATCATTAGATATGACGTCAATAG
AGAACAGAGCATTGGGGACATCCAGGTTCTAAATGGCTATTTTGTGCACTACTTTGCTCCTA
AAGACCTTCTCTTTTACCCAAGAATGTGGTATTCGTGCTTGACAGCAGTGCTTCTATGGTG
GGAACCAAACTCCGGCAGACCAAGGATGCCCTCTTCACAATTCTCCATGACCTCCGACCCCA
GGACCGTTTCAGTATCATTTGGATTTTCCAACCGGATCAAAGTATGGAAGGACCACTTGATAT
CAGTCACTCCAGACAGCATCAGGGATGGGAAAGTGTACATTACCATATGTCACCCACTGGA
GGCACAGACATCAACGGGGCCCTGCAGAGGGCCATCAGGCTCCTCAACAAGTACGTGGCCCA
CAGTGGCATTTGGAGACCGGAGCGTGTCCCTCATCGTCTTCTGACGGATGGGAAGCCACGG
TCGGGGAGACGCACACCTCAAGATCCTCAACAACACCCGAGAGGGCCGCCCCGAGGCCAAGTC
TGCATCTTACCATTGGCATCGGCAACGACGTGGACTTCAGGCTGCTGGAGAACTGTGCT
GGAGAACTGTGGCCTCACACGGCGCGTGCACGAGGAGGAGACGCAGGCTCGCAGCTCATCG
GGTTCTACGATGAAATCAGGACCCCGCTCCTCTCTGACATCCGCATCGATTATCCCCCAGC
TCAGTGGTGCAGGCCACCAAGACCTGTTCCCCACTACTTCAACGGCTCGGAGATCATCAT
TGCGGGGAAGCTGGTGGACAGGAAGCTGGATCACCTGCACGTGGAGGTCACCGCCAGCAACA
GTAAGAAATTCATCATCTGAAGACAGATGTGCCTGTGCGGCCTCAGAAGGCAGGGAAAGAT
GTCACAGGAAGCCCCAGGCCTGGAGGCGATGGAGAGGGGGACACCAACCACATCGAGCGTCT
CTGGAGCTACCTCACCACAAAGGAGCTGCTGAGCTCCTGGCTGCAAAGTGACGATGAACCGG
AGAAGGAGCGGCTGCGGCAGCGGGCCAGGCCCTGGCTGTGAGCTACCGCTTCTCACTCCC
TTCACCTCCATGAAGCTGAGGGGGCCGGTCCCACGCATGGATGGCCTGGAGGAGGCCACGG
CATGTGCGCTGCCATGGGACCCGAACCGGTGGTGCAGAGCGTGCAGAGGAGCTGGCACGCAGC
CAGGACCTTTGCTCAAGAAGCCAACTCCGTCAAAAAAAAAACAAAACAAAACAAAAAAGA
CATGGGAGAGATGGTGTTTTTCTCTCCACCACCTGGGGATACGAT**TGA**GAGATGGCCACCT
GCAAGCCAGGAAGACGGCCCTCACCAGACACCATGTCTGCTGGCACCTTGATCTTGGACCTC
CCAGCCTCCAGAACTGTGAGAAATAAATGTGTTTTGTTAAGCTAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

FIGURE 22

</usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA44192

<subunit 1 of 1, 694 aa, 1 stop

<MW: 77400, pI: 9.54, NX(S/T): 6

MLLLGLCLGLSLCVGSQEEAQSWGHSSEQDGLRVPRQVRLQLRLKTKPLMTEFSVKSTIIS
RYAFTTVSCRMLNRASEDQDIEFQMQUIPAAAFITNFTMLIGDKVYQGEITEREKKSGDRVKE
KRNKTTEENGEKGTETFRASAVIPSKDKAAFFLSYEELLQRRLGKYEHSISVRPQQLSGRLS
VDVNILESAGIASLEVLPLHNSRQRGSGRGEDDSGPPPSTVINQNETFANIIFKPTVVQQR
IAQNGILGDFIIRYDVNREQSIGDIQVLNGYFVHYFAPKDLPLPKNVVFLDSSASMVGTK
LRQTKDALFTILHDLRPQDRFSIIGFSNRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTD
INGALQRAIRLLNKYVAHSGIGDRSVSLIVFLTDGKPTVGETHTLKILNNTREAARGQVCIF
TIGIGNDVDVFRLLLEKLSLENCGLTRRVHEEEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVV
QATKTLFPNYFNGSEII IAGKLVDKLDHLHVEVTASNSKKFII LKTDVPVRPQKAGKDVTG
SPRPGGDGEGDTNHIERLWSYLTTKELLSSWLQSDDEPEKERLRQRAQALAVSYRFLTPFTS
MKLRGPVPRMDGLEEAHGMSAAMGPEPVVQSVRGAGTQPGPLLKKPNSVKKKQNKTKKRHGR
DGVFPLHHLGIR

Signal sequence.

amino acids 1-14

N-glycosylation sites.

amino acids 97-101, 127-131, 231-235, 421-425, 508-512, 674-678

Glycosaminoglycan attachment sites.

amino acids 213-217, 391-395

N-myristoylation sites.

amino acids 6-12, 10-16, 212-218, 370-376, 632-638, 638-644

0094432.083001
"00E80" 2444560

FIGURE 23

CGGACGCGTGGGGTGCCCGACATGGCGAGTGTAGTGCTGCCGAGCGGATCCCAGTGTGCGGC
GGCAGCGGCGGCGGCGGCCTCCCGGGCTCCGGCTTCTGCTGTTGCTCTTCTCCGCCGCGG
CACTGATCCCCACAGGTGATGGGCAGAATCTGTTTACGAAAGACGTGACAGTGATCGAGGGA
GAGGTTGCGACCATCAGTTGCCAAGTCAATAAGAGTGACGACTCTGTGATTCTAGCTACTGAA
TCCCAACAGGCAGACCATTATTTTCTAGGGACTTCAGGCCTTTGAAGGACAGCAGGTTTCAGT
TGCTGAATTTTTCTAGCAGTGAACCTCAAAGTATCATTGACAAACGTCTCAATTTCTGATGAA
GGAAGATACTTTTGCCAGCTCTATACCGATCCCCACAGGAAAGTTACACCACCATCACAGT
CCTGGTCCCACCACGTAATCTGATGATCGATATCCAGAAAGACACTGCGGTGGAAGGTGAGG
AGATTGAAGTCAACTGCACTGCTATGGCCAGCAAGCCAGCCACGACTATCAGGTGGTTCAAA
GGGAACACAGAGCTAAAAGGCAAATCGGAGGTGGAAGAGTGGTCAGACATGTACACTGTGAC
CAGTCAGCTGATGCTGAAGGTGCACAAGGAGGACGATGGGGTCCCAGTGATCTGCCAGGTGG
AGCACCTGCGGTCACTGGAAACCTGCAGACCCAGCGGTATCTAGAAGTACAGTATAAGCCT
CAAGTGCACATTCTAGATGACTTATCCTCTACAAGGCTTAACCCGGGAAGGGGACGCGCTTGA
GTTAACATGTGAAGCCATCGGGAAGCCCCAGCCTGTGATGGTAACTTGGGTGAGAGTCGATG
ATGAAATGCCTCAACACGCCGTACTGTCTGGGCCCAACCTGTTTCATCAATAACCTAAACAAA
ACAGATAATGGTACATACCGCTGTGAAGCTTCAAACATAGTGGGGAAAGCTCACTCGGATTA
TATGCTGTATGTATACGATCCCCCACAACCTATCCCTCCTCCCACAACAACCACCACCACCA
CCACCACCACCACCACCACCATTCTTACCATCATCACAGATTCCCGAGCAGGTGAAGAAGGC
TCGATCAGGGCAGTGGATCATGCCGTGATCGGTGGCGTCTGGCGGTGGTGGTGTTCGCCAT
GCTGTGCTTGCTCATCATTCTGGGGCGCTATTTTGCCAGACATAAAGGTACATACTTCACTC
ATGAAGCCAAAGGAGCCGATGACGCAGCAGACGCAGACACAGCTATAATCAATGCAGAAGGA
GGACAGAACAACTCCGAAGAAAAGAAAGAGTACTTCATCTAGATCAGCCTTTTTGTTTCAAT
GAGGTGTCCAACCTGGCCCTATTTAGATGATAAAGAGACAGTGATATTGG

FIGURE 25

GGGGCGGGTGGACGCGGACTCGAACGCAGTTGCTTCGGGACCCAGGACCCCCCTCGGGCCCGA
CCCGCCAGGAAAGACTGAGGCCGCGGCCTGCCCCGCCCCGGCTCCCTGCGCCGCGCCGCGCCTC
CCGGGACAGAAGATGTGCTCCAGGGTCCCTCTGCTGCTGCCGCTGCTCCTGCTACTGGCCCT
GGGGCCTGGGGTGCAGGGCTGCCCATCCGGCTGCCAGTGCAGCCAGCCACAGACAGTCTTCT
GCACTGCCCCGCCAGGGGACCACGGTGCCCCGAGACGTGCCACCCGACACGGTGGGGCTGTAC
GTCTTTGAGAACGGCATCACCATGCTCGACGCAAGCAGCTTTGCCGGCCTGCCGGGCCTGCA
GCTCCTGGACCTGTACAGAACCAGATCGCCAGCCTGCGCCTGCCCCGCCTGCTGCTGCTGG
ACCTCAGCCACAACAGCCTCCTGGCCCTGGAGCCCGGCATCCTGGACACTGCCAACGTGGAG
GCGCTGCGGGCTGGCTGGTCTGGGGCTGCAGCAGCTGGACGAGGGGCTCTTCAGCCGCTTGCG
CAACCTCCACGACCTGGATGTGTCCGACAACCAGCTGGAGCGAGTGCCACCTGTGATCCGAG
GCCTCCGGGGCCTGACGCGCCTGCGGCTGGCCGGCAACACCCGCATTGCCCAGCTGCGGGCC
GAGGACCTGGCCGGCCTGGCTGCCCTGCAGGAGCTGGATGTGAGCAACCTAAGCCTGCAGGC
CCTGCCTGGCGACCTCTCGGGCCTCTTCCCCCGCCTGCGGCTGCTGGCAGCTGCCCGCAACC
CCTTCAACTGCGTGTGCCCCCTGAGCTGGTTTGCCCCCTGGGTGCGCGAGAGCCACGTACAC
CTGGCCAGCCCTGAGGAGACGCGCTGCCACTTCCCGCCCAAGAACGCTGGCCGGCTGCTCCT
GGAGCTTGACTACGCCGACTTTGGCTGCCCAGCCACCACCACACAGCCACAGTGCCCAACA
CGAGGCCCCGTGGTGCGGGAGCCACAGCCTTGTCTTCTAGCTTGGCTCCTACCTGGCTTAGC
CCACAGCGCCGGCCACTGAGGCCCCCAGCCCGCCCTCCACTGCCCCACCGACTGTAGGGCC
TGTCCCCCAGCCCCAGGACTGCCACCGTCCACCTGCCTCAATGGGGGCACATGCCACCTGG
GGACACGGCACCACTGGCGTGCTTGTGCCCCGAAGGCTTCACGGGCTGTACTGTGAGAGC
CAGATGGGGCAGGGGACACGGCCCAGCCCTACACCAGTCACGCCGAGGGCCACCACGGTCCCT
GACCCTGGGCATCGAGCCGGTGAGCCCCACCTCCCTGCGCGTGGGGCTGCAGCGCTACCTCC
AGGGGAGCTCCGTGCAGCTCAGGAGCCTCCGTCTCACCTATCGCAACCTATCGGGCCCTGAT
AAGCGGCTGGTGACGCTGCGACTGCCTGCCTCGCTCGCTGAGTACACGGTCACCCAGCTGCG
GCCAACGCCACTTACTCCGTCTGTGTATGCCTTTGGGGCCCCGGGCGGGTGCCGGAGGGCG
AGGAGGCCTGCGGGGAGGCCCATAACCCCCAGCCGTCCACTCCAACCACGCCCCAGTCACC
CAGGCCCCGCGAGGGCAACCTGCCGCTCCTCATTGCGCCCCGCCCTGGCCGCGGTGCTCCTGGC
CGCGCTGGCTGCGGTGGGGGCAGCCTACTGTGTGCGGCGGGGGCGGGCCATGGCAGCAGCGG
CTCAGGACAAAGGGCAGGTGGGGCCAGGGGCTGGGGCCCCTGGAAGTGGAGGGAGTGAAGGTC
CCCTTGAGGCCAGGCCCCGAAGGCAACAGAGGGCGGTGGAGAGGCCCTGCCCAGCGGGTCTGA
GTGTGAGGTGCCACTCATGGGCTTCCCAGGGCCTGGCCTCCAGTCACCCCTCCACGCAAAGC
CCTACATCTAAGCCAGAGAGAGACAGGGCAGCTGGGGCCGGGCTCTCAGCCAGTGAGATGGC
CAGCCCCCTCCTGCTGCCACACCACGTAAGTTCTCAGTCCCAACCTCGGGGATGTGTGCAGA
CAGGGCTGTGTGACCACAGCTGGGCCCTGTTCCCTCTGGACCTCGGTCTCCTCATCTGTGAG
ATGCTGTGGCCAGCTGACGAGCCCTAACGTCCCCAGAACCGAGTGCCTATGAGGACAGTGT
CCGCCCTGCCCTCCGCAACGTGCAGTCCCTGGGCACGGCGGGGCCCTGCCATGTGCTGGTAAC
GCATGCCTGGGCCCTGCTGGGCTCTCCCACTCCAGGCGGACCCTGGGGGCCAGTGAAGGAAG
CTCCCGGAAAGAGCAGAGGGAGAGCGGGTAGGCGGCTGTGTGACTCTAGTCTTGCCCCAGG
AAGCGAAGGAACAAAAGAACTGGAAAGGAAGATGCTTTAGGAACATGTTTTGCTTTTTTAA
AATATATATATATTTATAAGAGATCCTTTCCCATTTATTCTGGGAAGATGTTTTTCAAACCTC
AGAGACAAGGACTTTGGTTTTTGTAAAGACAAACGATGATATGAAGGCCTTTTGTAAAGAAAA
ATAAAAAAAAAAA

090443" 0330

Country	Year	Population (millions)	Urban population (millions)	Urban population (%)	Population density (per sq km)	Urban population density (per sq km)	Population growth rate (%)	Urban population growth rate (%)	Population growth rate (%)	Urban population growth rate (%)	Population growth rate (%)	Urban population growth rate (%)
Algeria	1980	10.0	4.0	40.0	100.0	250.0	1.5	2.5	1.5	2.5	1.5	2.5
Algeria	1985	10.5	4.5	42.9	105.0	262.5	1.8	3.0	1.8	3.0	1.8	3.0
Algeria	1990	11.0	5.0	45.5	110.0	275.0	2.0	3.5	2.0	3.5	2.0	3.5
Algeria	1995	11.5	5.5	47.8	115.0	287.5	2.2	4.0	2.2	4.0	2.2	4.0
Algeria	2000	12.0	6.0	50.0	120.0	300.0	2.5	4.5	2.5	4.5	2.5	4.5
Algeria	2005	12.5	6.5	52.0	125.0	312.5	2.8	5.0	2.8	5.0	2.8	5.0
Algeria	2010	13.0	7.0	53.8	130.0	325.0	3.0	5.5	3.0	5.5	3.0	5.5
Algeria	2015	13.5	7.5	55.6	135.0	337.5	3.2	6.0	3.2	6.0	3.2	6.0
Algeria	2020	14.0	8.0	57.1	140.0	350.0	3.5	6.5	3.5	6.5	3.5	6.5
Algeria	2025	14.5	8.5	58.6	145.0	362.5	3.8	7.0	3.8	7.0	3.8	7.0
Algeria	2030	15.0	9.0	60.0	150.0	375.0	4.0	7.5	4.0	7.5	4.0	7.5
Algeria	2035	15.5	9.5	61.3	155.0	387.5	4.2	8.0	4.2	8.0	4.2	8.0
Algeria	2040	16.0	10.0	62.5	160.0	400.0	4.5	8.5	4.5	8.5	4.5	8.5
Algeria	2045	16.5	10.5	63.6	165.0	412.5	4.8	9.0	4.8	9.0	4.8	9.0
Algeria	2050	17.0	11.0	64.7	170.0	425.0	5.0	9.5	5.0	9.5	5.0	9.5
Algeria	2055	17.5	11.5	65.7	175.0	437.5	5.2	10.0	5.2	10.0	5.2	10.0
Algeria	2060	18.0	12.0	66.7	180.0	450.0	5.5	10.5	5.5	10.5	5.5	10.5
Algeria	2065	18.5	12.5	67.6	185.0	462.5	5.8	11.0	5.8	11.0	5.8	11.0
Algeria	2070	19.0	13.0	68.4	190.0	475.0	6.0	11.5	6.0	11.5	6.0	11.5
Algeria	2075	19.5	13.5	69.2	195.0	487.5	6.2	12.0	6.2	12.0	6.2	12.0
Algeria	2080	20.0	14.0	70.0	200.0	500.0	6.5	12.5	6.5	12.5	6.5	12.5
Algeria	2085	20.5	14.5	70.7	205.0	512.5	6.8	13.0	6.8	13.0	6.8	13.0
Algeria	2090	21.0	15.0	71.4	210.0	525.0	7.0	13.5	7.0	13.5	7.0	13.5
Algeria	2095	21.5	15.5	72.1	215.0	537.5	7.2	14.0	7.2	14.0	7.2	14.0
Algeria	2100	22.0	16.0	72.7	220.0	550.0	7.5	14.5	7.5	14.5	7.5	14.5
Algeria	2105	22.5	16.5	73.3	225.0	562.5	7.8	15.0	7.8	15.0	7.8	15.0
Algeria	2110	23.0	17.0	73.9	230.0	575.0	8.0	15.5	8.0	15.5	8.0	15.5
Algeria	2115	23.5	17.5	74.5	235.0	587.5	8.2	16.0	8.2	16.0	8.2	16.0
Algeria	2120	24.0	18.0	75.0	240.0	600.0	8.5	16.5	8.5	16.5	8.5	16.5
Algeria	2125	24.5	18.5	75.5	245.0	612.5	8.8					

<MW: 63030, pI: 7.24, NX(S/T): 3

MCSRVPLLLPLLLLLLALGPGVQGCPSGCQCSQPQTVFCTARQGTTPRDPVPPDTVGLYVFEN
GITMLDASSFAGLPGLQLLDLSQNQIASLRLPRLLLLDLSHNSLLALEPGILDANVEALRL
AGLGLQQLDEGLFSRLRNLDLDVSDNQLERVPPVIRGLRGLTRLRLAGNTRIAQLRPEDLA
GLAALQELDVSNLSLQALPGDLSGLFPRLRLAAARNPFNCVCPLSWFGPWVRESHVTLASP
EETRCHFPFKNAGRLLLELDYADFGCPATTTTATVPTTRPVVREPTALSSSSLAPTWLSPTAP
ATEAPSPSTAPPTVGPVPQPQDCPPSTCLNGGTCHLGRHHLACLCPEGFTGLYCESQMGQ
GTRPSPTPVTTPRPPRSLTGLIEPVSPTSRLRVGLQRYLQGSSVQLRSLRLTYRNLSPDKRLV
TLRLPASLAEYTVTQLRPNATYSVCVMPLGPGRVPEGEEACGEAHTPPAVHSNHAPVTQARE
GNLPLLIAPALAAVLLAALAAVGAAYCVRRGRAMAAAAQDKGQVGPAGPLELEGVKVPLEP
GPKATEGGGEALPSGSECEVPLMGFPGPGLOSPLHAKPYI

amino acids 1-23

amino acids 501-522

amino acids 198-202, 425-429, 453-457

amino acids 262-270

amino acids 23-29, 27-33, 112-118, 273-279, 519-525, 565-571

amino acids 14-25

amino acids 355-367

amino acids 122-144, 194-216

FIGURE 27

GGCACTAGGACAACCTTCTTCCCTTCTGCACCACTGCCCCGTACCCTTACCCGCCCCGCCACC
TCCTTGCTACCCCACTCTTGAAACCACAGCTGTTGGCAGGGTCCCCAGCTCATGCCAGCCTC
ATCTCCTTTCTTGCTAGCCCCCAAAGGGCCTCCAGGCAACATGGGGGGCCCAGTCAGAGAGC
CGGCACTCTCAGTTGCCCTCTGGTTGAGTTGGGGGGCAGCTCTGGGGGGCCGTGGCTTGTGCC
ATGGCTCTGCTGACCCAACAAACAGAGCTGCAGAGCCTCAGGAGAGAGGTGAGCCGGCTGCA
GGGGACAGGAGGCCCCCTCCAGAATGGGGAAGGGTATCCCTGGCAGAGTCTCCCGGAGCAGA
GTTCCGATGCCCTGGAAGCCTGGGAGAATGGGGAGAGATCCCGGAAAAGGAGAGCAGTGCTC
ACCCAAAAACAGAAGAAGCAGCACTCTGTCCTGCACCTGGTTCCCATTAACGCCACCTCCAA
GGATGACTCCGATGTGACAGAGGTGATGTGGCAACCAGCTCTTAGGCGTGGGAGAGGCCTAC
AGGCCCAAGGATATGGTGTCCGAATCCAGGATGCTGGAGTTTATCTGCTGTATAGCCAGGTC
CTGTTTCAAGACGTGACTTTCACCATGGGTCAGGTGGTGTCTCGAGAAGGCCAAGGAAGGCA
GGAGACTCTATTCCGATGTATAAGAAGTATGCCCTCCCACCCGGACCGGGCCTACAACAGCT
GCTATAGCGCAGGTGTCTTCCATTTACACCAAGGGGATATTCTGAGTGTCATAATTCCCCGG
GCAAGGGCGAAACTTAACCTCTCTCCACATGGAACCTTCCTGGGGTTTGTGAAACTGTGATT
GTGTTATAAAAAGTGGCTCCCAGCTTGGAAGACCAGGGTGGGTACATACTGGAGACAGCCAA
GAGCTGAGTATATAAAGGAGAGGGAATGTGCAGGAACAGAGGCATCTTCCTGGGGTTTGGCTC
CCCGTTCCTCACTTTTCCCTTTTCATTCCCACCCCCTAGACTTTGATTTTACGGATATCTTG
CTTCTGTTCCCCATGGAGCTCCG

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2433	2434	2435	2436	2437	2438	2439	2440	2441	2442	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

MPASSPFLLLAPKGP PGNMGGPVREPALSVLWLSWGAALGAVACAMALLTQQTELQSLRREV
SRLQGTGGPSQNGEGYPWQSLPEQSSDALEAWENGERSRKRRAVLTQKQKKQHSLVHLVPIN
ATSKDDSDVTEVMWQPALRRGRGLQAQGYGVR IQDAGVYLLYSQVLFQDVTFTMGQVVSREG
QGRQETLFR CIRSMPSHPDRAYNSCYSGVFHLHQGDILSVI IPRARAKLNLSPHGTFLGFVKL

amino acids 1-40

amino acids 124-128

amino acids 156-164

amino acids 36-42, 40-46, 179-185, 242-248

amino acids 34-45

FIGURE 29

CACTTTCTCCCTCTCTTCTTTACTTTTCGAGAAACCGCGCTTCCGCTTCTGGTTCGCAGAGAC
CTCGGAGACCGCGCCGGGAGACGGAGGTGCTGTGGGTGGGGGGACCTGTGGCTGCTCGTA
CCGCCCCCACCCTCCTCTTCTGCACTGCCGTCTCCGGAAGACCTTTTCCCTGCTCTGTT
TCCTTCACCGAGTCTGTGCATCGCCCCGGACCTGGCCGGGAGGAGGCTTGGCCGGCGGGAGA
TGCTCTAGGGGCGGCGCGGGAGGAGCGGCCGGCGGGACGGAGGGCCCGGCAGGAAGATGGGC
TCCCGTGGACAGGGACTCTTGCTGGCGTACTGCCTGCTCCTTGCCTTTGCCTCTGGCCTGGT
CCTGAGTCGTGTGCCCCATGTCCAGGGGGAACAGCAGGAGTGGGAGGGGACTGAGGAGCTGC
CGTCGCCTCCGGACCATGCCGAGAGGGCTGAAGAACAACATGAAAAATACAGGCCCAGTCAG
GACCAGGGGCTCCCTGCTTCCCGGTGCTTGCCTGCTGTGACCCCGGTACCTCCATGTACCC
GGCGACCGCCGTGCCCCAGATCAACATCACTATCTTGAAAGGGGAGAAGGGTGACCGCGGAG
ATCGAGGCCTCCAAGGGAAATATGGCAAAACAGGCTCAGCAGGGGGCCAGGGGCCACACTGGA
CCCAAAGGGCAGAAGGGCTCCATGGGGGCCCCCTGGGGAGCGGTGCAAGAGCCACTACGCCGC
CTTTTCGGTGGGCCGGAAGAAGCCCATGCACAGCAACCACTACTACCAGACGGTGATCTTCG
ACACGGAGTTCGTGAACCTCTACGACCACTTCAACATGTTACCGGCAAGTTCTACTGCTAC
GTGCCCCGGCCTCTACTTCTTCAGCCTCAACGTGCACACCTGGAACCAGAAGGAGACCTACCT
GCACATCATGAAGAACGAGGAGGAGGTGGTGATCTTGTTTCGCGCAGGTGGGCGACCGCAGCA
TCATGCAAAGCCAGAGCCTGATGCTGGAGCTGCGAGAGCAGGACCAGGTGTGGGTACGCCTC
TACAAGGGCGAACGTGAGAACGCCATCTTCAGCGAGGAGCTGGACACCTACATCACCTTCAG
TGGCTACCTGGTCAAGCACGCCACCGAGCCCCTAGCTGGCCGGCCACCTCCTTTCTCTCGCC
ACCTTCCACCCCTGCGCTGTGCTGACCCCAACGCCTCTTCCCCGATCCCTGGACTCCGACTC
CCTGGCTTTGGCATTCACTGAGACGCCCTGCACACACAGAAAGCCAAAGCGATCGGTGCTCC
CAGATCCCGCAGCCTCTGGAGAGAGCTGACGGCAGATGAAATCACCAGGGCGGGGCACCCGC
GAGAACCCTCTGGGACCTTCCGCGGCCCTCTCTGCACACATCCTCAAGTGACCCCGCACGGC
GAGACGCGGGTGGCGGCAGGGCGTCCAGGGTGCGGCACCGCGGCTCCAGTCTTGGAAATA
ATTAGGCAAATTCTAAAGGTCTCAAAGGAGCAAAGTAAACCGTGGAGGACAAAGAAAAGGG
TTGTTATTTTTGTCTTTCCAGCCAGCCTGCTGGCTCCCAAGAGAGAGGCCTTTTCAGTTGAG
ACTCTGCTTAAGAGAAGATCCAAAGTTAAAGCTCTGGGGTCAAGGGAGGGGCGGGGGCAGG
AAACTACCTCTGGCTTAATTCTTTTAAGCCACGTAGGAACCTTCTTGAGGGATAGGTGGACC
CTGACATCCCTGTGGCCTTGCCCAAGGGCTCTGCTGGTCTTTCTGAGTCACAGCTGCGAGGT
GATGGGGGCTGGGGCCCCAGGCGTCAAGCCTCCAGAGGGACAGCTGAGCCCCCTGCCTTGGC
TCCAGGTTGGTAGAAGCAGCCGAAGGGCTCCTGACAGTGGCCAGGGACCCCTGGGTCCCCA
GGCCTGCAGATGTTTCTATGAGGGGCAGAGCTCCTTGGTACATCCATGTGTGGCTCTGCTCC
ACCCCTGTGCCACCCAGAGCCCTGGGGGGTGGTCTCCATGCCTGCCACCCTGGCATCGGCT
TTCTGTGCCGCTCCACACAAATCAGCCCCAGAAGGCCCGGGGCCTTGGCTTCTGTTTTT
TATAAAACACCTCAAGCAGCACTGCAGTCTCCATCTCCTCGTGGGCTAAGCATCACCGCTT
CCACGTGTGTTGTGTTGGTTGGCAGCAAGGCTGATCCAGACCCCTTCTGCCCCACTGCCCT
CATCCAGGCCTCTGACCAGTAGCCTGAGAGGGGCTTTTTCTAGGCTTCAAGCAGGGGAGAG
CTGGAAGGGGCTAGAAAGCTCCCGCTTGTCTGTTTCTCAGGCTCCTGTGAGCCTCAGTCCTG
AGACCAGAGTCAAGAGGAAGTACACGTCCCAATCACCCGTGTCAAGATTCACTCTCAGGAGC
TGGGTGGCAGGAGAGGCAATAGCCCTGTGGCAATTGCAGGACCAGCTGGAGCAGGGTTGCG
GTGTCTCCACGGTGTCTCTGCCCTGCCCATGGCCACCCAGACTCTGATCTCCAGGAACCC
ATAGCCCTCTCCACCTCACCCCATGTTGATGCCAGGGTCACTCTTGCTACCCGCTGGGCC
CCCAAACCCCGCTGCCTCTCTTCCCTTCCCCCATCCCCACCTGGTTTTGACTAATCCTGC
TTCCCTCTCTGGGCCTGGCTGCCGGGATCTGGGGTCCCTAAGTCCCTCTCTTTAAAGAACTT
CTGCGGGTCAAGCTCTGAAGCCGAGTTGCTGTGGGCGTGCCCGGAAGCAGAGCGCCACACTC
GCTGCTTAAGCTCCCCAGCTCTTTCCAGAAACATTAAACTCAGAATTGTGTTTTCAA

FIGURE 30

></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA41234

><subunit 1 of 1, 281 aa, 1 stop

><MW: 31743, pI: 6.83, NX(S/T): 1

MGSRGQGLLLAYCLLLAFASGLVLSRVPHVQGEQQEWEGTEELPSPPDHAERAEEQHEKYRP
SQDQGLPASRCLRCCDPGTSMPATAVPQINITILKGEKGDGRGLQGKYGKTGSAGARGH
TGPKGQKGSMPGERCKSHYAAFSVGRKKPMHSNHYYQTVIFDTEFVNLYDHFNMFTGKFY
CYVPGLYFFSLNVHTWNQKETYLHIMKNEEEVVILFAQVGDRSIMQSQSLMLELREQDQVWV
RLYKGERENAIFSEELDTYITFSGYLVKHATEP

Signal sequence.

amino acids 1-25

N-glycosylation site.

amino acids 93-97

N-myristoylation sites.

amino acids 7-13, 21-27, 67-73, 117-123, 129-135

Amidation site.

amino acids 150-154

Cell attachment sequence.

amino acids 104-107

FIGURE 30 "22444660"

FIGURE 31

GCGGAGCATCCGCTGCGGTCCTCGCCGAGACCCCCGCGCGGATTGCGCCGGTCCTTCCCGCGG
GCGCGACAGAGCTGTCCTCGCACCTGGATGGCAGCAGGGGCGCCGGGGTCCTCTCGACGCCA
GAGAGAAATCTCATCATCTGTGCAGCCTTCTTAAAGCAAACCTAAGACCAGAGGGAGGATTAT
CCTTGACCTTTGAAGACCAAACTAAACTGAAATTTAAATGTTCTTCGGGGGAGAAGGGAG
CTTGACTTACACTTTGGTAATAATTTGCTTCCTGACACTAAGGCTGTCTGCTAGTCAGAATT
GCCTCAAAAAGAGTCTAGAAGATGTTGTGATTGACATCCAGTCATCTCTTTCTAAGGGAATC
AGAGGCAATGAGCCCGTATATACTTCAACTCAAGAAGACTGCATTAATTCTTGCTGTTCAAC
AAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTA
GACAACCCAACTGCTACCTATTTTTCTGTCCCAACGAGGAAGCCTGTCCATTGAAACCAGCA
AAAGGACTTATGAGTTACAGGATAATTACAGATTTTCCATCTTTGACCAGAAATTTGCCAAG
CCAAGAGTTACCCAGGAAGATTCTCTCTTACATGGCCAATTTTCACAAGCAGTCACTCCCC
TAGCCCATCATCACACAGATTATTCAAAGCCCACCGATATCTCATGGAGAGACACACTTTCT
CAGAAGTTTGGATCCTCAGATCACCTGGAGAACTATTTAAGATGGATGAAGCAAGTGCCCA
GCTCCTTGCTTATAAGGAAAAAGGCCATTCTCAGAGTTTACAATTTTCTCTGATCAAGAAA
TAGCTCATCTGCTGCCTGAAAATGTGAGTGCCTCCAGCTACGGTGGCAGTTGCTTCTCCA
CATAACACCTCGGCTACTCCAAAGCCCGCCACCCTTCTACCCACCAATGCTTCAGTGACACC
TTCTGGGACTTCCCAGCCACAGCTGGCCACCACAGCTCCACCTGTAACCACTGTCACTTCTC
AGCCTCCCACGACCCTCATTCTACAGTTTTTACACGGGCTGCGGCTACACTCCAAGCAATG
GCTACAACAGCAGTTCTGACTACCACCTTTCAGGCACCTACGGACTCGAAAGGCAGCTTAGA
AACCATAACGTTTACAGAAATCTCCAACCTTAACTTTGAACACAGGGAATGTGTATAACCCTA
CTGCACTTTCTATGTCAAATGTGGAGTCTTCCACTATGAATAAACTGCTTCCTGGGAAGGT
AGGGAGGCCAGTCCAGGCAGTTCTCCAGGGCAGTGTTCCAGAAAATCAGTACGGCCTTCC
ATTTGAAAAATGGCTTCTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTGTTGATAGGCC
TCGTCCTCCTGGGTAGAATCCTTTCGGAATCACTCCGCAGGAAACGTTACTCAAGACTGGAT
TATTTGATCAATGGGATCTATGTGGACATCTAAGGATGGAACCTCGGTGTCTCTTAATTCATT
TAGTAACCAGAAGCCCAAATGCAATGAGTTTTCTGCTGACTTGCTAGTCTTAGCAGGAGGTTG
TATTTTGAAGACAGGAAAATGCCCCCTTCTGCTTCTCTTTTTTTTTTGGAGACAGAGTCTT
GCTCTGTTGCCAGGCTGGAGTGCAGTAGCACGATCTCGGCTCTCACCGCAACCTCCGTCTC
CTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTAAGTATCTGGGATTACAGGCATGTGCCA
CCACACCTGGGTGATTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCATGTTGGTCAGGCTG
GTCTCAAACCTCCTGACCTAGTGATCCACCCTCCTCGGCCTCCCAAAGTGCTGGGATTACAGG
CATGAGCCACCACAGCTGGCCCCCTTCTGTTTTATGTTTTGGTTTTTGAAGAAGGAATGAAGTG
GGAACCAAATTAGGTAATTTTGGGTAATCTGTCTCTAAAATATTAGCTAAAAACAAAGCTCT
ATGTAAAGTAATAAAGTATAATTGCCATATAAATTTCAAATTTCAACTGGCTTTTATGCAAA
GAAACAGGTTAGGACATCTAGGTTCCAATTCATTACATTCTTGGTTCCAGATAAAATCAAC
TGTTTATATCAATTTCTAATGGATTTGCTTTTCTTTTATATGGATTCCCTTTAAACTTATT
CCAGATGTAGTTCCTTCCAATTAAATATTTGAATAAATCTTTTGTACTCAA

FIGURE 32

></usr/seqdb2/sst/DNA/Dnaseqs.min/ss.DNA45410

><subunit 1 of 1, 431 aa, 1 stop

><MW: 46810, pI: 6.45, NX(S/T): 6

MFFGGEGSLTYTLVIICFLTLRLSASQNCLKKSLEDVVIDIQSSLSKGIRGNEPVYTSTQED
CINSCCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRIITDFP
SLTRNLPSQELPQEDSL LHGQFSQAVTPLAHHHTDYSKPTDISWRDTLSQKFGSSDHLEKLF
KMDEASAQLLAYKEKGHSQSSQFSSDQEIAHLLPENVSALPATVAVASPHTTSATPKPATLL
PTNASVTPSGTSQPQLATTAPPVTTVTSQPPTTLISTVFTRAAATLQAMATTAVLTTTFQAP
TDSKGSLETIPFTEISNLTNTGNVYNPTALSMSNVESSTMNK TASWEGREASPGSSSQGSV
PENQYGLPFEKWLLIGSLLFGVLFLVIGLVLLGRILSESLRRKRYRLDYLINGIYVDI

Signal sequence.

amino acids 1-25

Transmembrane domain.

amino acids 384-405

N-glycosylation sites.

amino acids 72-76, 222-226, 251-255, 327-331, 352-356

cAMP- and cGMP-dependent protein kinase phosphorylation site.

amino acids 415-419

Tyrosine kinase phosphorylation site.

amino acids 50-57

N-myristoylation sites.

amino acids 4-10, 48-54, 315-321

FIGURE 32

FIGURE 33

GCGGCACCTGGAAGATGCGCCCATTGGCTGGTGGCCTGCTCAAGGTGGTGTTCGTGGTCTTC
GCCTCCTTGTGTGCCTGGTATTCGGGGTACCTGCTCGCAGAGCTCATTCAGATGCACCCCT
GTCCAGTGCTGCCTATAGCATCCGCAGCATCGGGGAGAGGCCTGTCCTCAAAGCTCCAGTCC
CCAAAAGGCAAAAATGTGACCACTGGACTCCCTGCCCATCTGACACCTATGCCTACAGGTTA
CTCAGCGGAGGTGGCAGAAGCAAGTACGCCAAAATCTGCTTTGAGGATAACCTACTTATGGG
AGAACAGCTGGGAAATGTTGCCAGAGGAATAAACATTGCCATTGTCAACTATGTAAGTGGGA
ATGTGACAGCAACACGATGTTTTGATATGTATGAAGGCGATAACTCTGGACCGATGACAAAG
TTTATTCAGAGTGCTGCTCCAAAATCCCTGCTCTTCATGGTGACCTATGACGACGGAAGCAC
AAGACTGAATAACGATGCCAAGAATGCCATAGAAGCACTTGGAAGTAAAGAAATCAGGAACA
TGAAATTCAGGTCTAGCTGGGTATTTATTGCAGCAAAAGGCTTGGAACCTCCCTTCCGAAATT
CAGAGAGAAAAGATCAACCACTCTGATGCTAAGAACAACAGATATTCTGGCTGGCCTGCAGA
GATCCAGATAGAAGGCTGCATACCCAAAGAACGAAGCTTGACACTGCAGGGTCCTGAGTAAAT
GTGTTCTGTATAAACAAATGCAGCTGGAATCGCTCAAGAATCTTATTTTTCTAAATCCAACA
GCCCATATTTGATGAGTATTTTGGGTTTGTGTAAACCAATGAACATTTGCTAGTTGTATCA
AATCTTGGTACGCAGTATTTTATACCAGTATTTTATGTAGTGAAGATGTCAATTAGCAGGA
AACTAAAATGAATGGAAATTCTTAAAAAAAAA

0944303001
T00E80" 2E+H60

General Information		Study Design		Study Population		Intervention		Outcome Measures		Statistical Analysis		
Study Title	Effect of a new drug on blood pressure	Randomized Controlled Trial	Parallel Group	100 patients	100 patients	Drug A	Drug B	Blood Pressure (mmHg)	Side Effects (%)	Mean Difference	95% CI	
Study ID	12345	Phase	II	Age (years)	50 ± 10	Duration (weeks)	12	Baseline (mmHg)	120/80	Mean	SD	15
Study Date	2023-2024	Location	USA	Gender	50% Male	Intervention	Drug A	Week 12 (mmHg)	110/70	Mean	SD	10
Study Status	Completed	Registration	ClinicalTrials.gov	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Funding	Government	Protocol	1.0	Intervention	Drug A	Week 12 (mmHg)	110/70	Mean	SD	10	95% CI	
Study Lead	Dr. John Doe	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Ethics	Approved	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Results	Significant	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Conclusion	Drug A is superior	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Limitations	Small sample size	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Future Work	Larger trial needed	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study References	1, 2, 3, 4, 5	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Acknowledgments	Thank you to all participants	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Contact Information	Dr. John Doe, 12345	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Appendix	See supplementary materials	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Bibliography	1. Smith et al. 2020	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Glossary	See supplementary materials	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Disclaimer	This study is not a medical recommendation	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12
Study Footer	Page 1 of 1	Statistical Analysis	Intention-to-Treat	Dropouts	5	Side Effects	5%	Week 12 (mmHg)	115/75	Mean	SD	12

><subunit 1 of 1, 235 aa, 1 stop

MRPLAGLLKVVVFVVFASLCAWYSGYLLAELIPDAPLSSAAYSIRSIGERPVLKAPVPKRQK
CDHWTPCPSDTYAYRLLSGGGRSKYAKICFEDNLLMGEQLGNVARGINIAIVNYVTGNVTAT
RCFDMYEGDNSGPMTKFIQSAAPKSLLFMVTYDDGSTRLNNDAKNAIEALGSKEIRNMKFRS
SWVFIAAKGLELPSEIQREKINHSDAKNNRYSGWPAEIQIEGCI PKERS

amino acids 1-20

amino acids 120-124, 208-212

amino acids 80-84

amino acids 81-87, 108-114, 119-125